Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management

Koo, Kevin M.; Mainwaring, Paul N.; Tomlins, Scott A.

doi:10.1038/s41585-019-0178-2

Cited by 97 publications

(77 citation statements)

References 245 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When we merge the understanding of biosensor concepts with the highly promising field of nanotechnology it develops a new area of disease diagnostics i.e. nanodiagnostics [31]. In this area we pay an attention to the design and modification of nanomaterials for improving cancer detection and treatment.…”

Section: Definition and Conceptual Idea Of Nanobiosensormentioning

confidence: 99%

Nano-Biosensors for Cancer Diagnostics: Current Status and Future Prospects

Karki¹,

Bisht²,

Shahi³

et al. 2019

JNST

View full text Add to dashboard Cite

Cancer is one of the leading life-threatening diseases all over the globe which costs highest mortality rates. Early detection of cancer increases the chance of a cure and survival rates but unfortunately mostly cancers are diagnosed only after they have metastasized throughout the body. The list of the biomarkers associated with over 200 types of cancer has witnessed a significant increase in the recent past however the highly sensitive and specific biomarkers are still need of time. Biosensors are devices that are designed to detect a specific biological analyte by converting the complex biological reactions into an electrical signal whose intensity is associated with the concentration of the analyte. Nanotechnology with nanomaterials improves and modifies the biorecognition element part to improve the biosensing phenomenon and makes it one of the hottest topics attracting scientific fraternity. Use of diverse numbers of nanomaterials with good electrical and sensing properties has promised a smarter and faster detection with better reproducibility. This review briefly summarizes the few different types of biosensors based on different types of nanomaterials for cancer biomarker detection. This paper also highlights the obstacles related to their developmental and implicational aspects.

show abstract

Section: Definition and Conceptual Idea Of Nanobiosensormentioning

confidence: 99%

Nano-Biosensors for Cancer Diagnostics: Current Status and Future Prospects

Karki¹,

Bisht²,

Shahi³

et al. 2019

JNST

View full text Add to dashboard Cite

show abstract

“…Microfluidic technologies offer great potential to revolutionize the way for sampling, sample separation, mixing, chemical reaction, and detection. In this mode, advances of microfluidics in past decades have significantly promote the development of analytical science in many ways …”

Section: Introductionmentioning

confidence: 99%

Microfluidics for Biomedical Analysis

et al. 2019

View full text Add to dashboard Cite

Many new techniques and materials have been applied to microfluidic systems in the past decade, and integrated microfluidic chips have become powerful platforms for realizing highly sensitive, high throughput, and low‐cost analysis. This article reviews the latest advancements of microfluidic platforms for biological and biomedical analysis in the fields of fundamental biology research, clinical application, food safety, and environmental monitoring, with a focus on nucleic acid‐based molecular diagnosis and protein‐based immunodiagnosis. The combination of microfluidics with advanced techniques (e.g., nanotechnology, 3D printing, deep learning) would offer innovative new tools for bioanalyses. The current challenges and the future developments of microfluidic technologies for clinical applications are also discussed. It is anticipated that this review will be beneficial to promoting microfluidics toward a broad range of applications in the future.

show abstract

“…[2][3][4][5][6][7] Moreover, recent advancements in analysis include the measurement of the type 2 transmembrane serine protease (TMPRSS), ETS-related gene (ERG), prostate health index (PHI), and [À2] proPSA (p2PSA). 8,9 Additionally, HOXC6 and DLX1 expression in urine are used for detecting early-stage PCa to aid selecting men for biopsy. 10 These potential biomarkers for PCa detection have been evaluated alone or in combination.…”

Section: Introductionmentioning

confidence: 99%

“…10 These potential biomarkers for PCa detection have been evaluated alone or in combination. [8][9][10] In this study, we focused on the potential role of an altered PSA glycosylation pattern as a specific biomarker for detecting clinically significant PCa. Glycosylation is a biologically important posttranslational modification involved in many physiological processes, including cell adhesion, differentiation, and protein folding.…”

Section: Introductionmentioning

confidence: 99%